Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Radiosurgery for Brain Metastases
NCT02978404Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Jun 2017
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in brain metastases, sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Intracranial progression-free survival at 1 year. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02978404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978404.